Earnings ·
Neuronetics reported second quarter 2026 total revenue of $41.6 million, a 9.1% increase from the prior year period
STIMNeuronetics, Inc.
Neuronetics reported second quarter 2026 total revenue of $41.6 million, a 9.1% increase from the prior year period. Greenbrook clinic revenue grew 16.8% to $26.9 million, while NeuroStar device revenue declined 2.7% to $14.7 million. The company achieved positive adjusted EBITDA of $0.3 million compared to a loss of $5.6 million in the prior year quarter and reported a net loss of $3.4 million versus $10.1 million previously. Management updated its full-year 2026 revenue guidance to $160–$164 million and operating expense guidance to exclude stock-based compensation, projecting adjusted operating expenses between $91 million and $96 million. The company also appointed Nir Naor as CFO and Rob Greene as SVP of Sales. Neuronetics operates in the interventional mental health industry, providing transcranial magnetic stimulation technology and direct patient care through its Greenbrook clinic network.